Document:

EXHIBIT
        10.1

       

    

    EXCLUSIVE
      LICENSE AGREEMENT

    

    This
      is an Exclusive License Agreement,
      entered
      into May 12, 2006 and effective as of January 24, 2006, between Technology
      Innovations, LLC (“TI”), a New York limited liability company having an address
      of 150 Lucius Gordon Drive, Suite 215, West Henrietta, NY 14586, and
      NaturalNano, Inc., (“NaturalNano”), a Nevada corporation having an address of
      150 Lucius Gordon Drive, Suite 115, West Henrietta, NY 14586.

    

    Background.
      The
      parties entered into and wish to replace the Exclusive License Agreement, dated
      April 27, 2005 (the “Prior Agreement”). 

    

    TI
      owns
      and is willing to license the Patent Rights and Confidential Information
      (defined below) to NaturalNano exclusively for the Licensed Field, subject
      to
      the terms and conditions of this Agreement. NaturalNano wishes to obtain such
      a
      license.

    

    Therefore,
      in
      consideration of the promises set forth in this Agreement, the parties agree
      as
      follows:

    

    
      	
              1)

            	
              Definitions.
                As
                used in this Agreement:

            

    

    

    
      	 	
              a)

            	
              “Affiliate”
                means an entity that controls, is controlled by, or is under common
                control with NaturalNano or TI, as applicable. For this purpose,
“control”
                means (i) the power to direct or cause the direction of the
                management and affairs of the entity, whether by direct or indirect
                ownership of voting stock, positions on the board of directors, contract,
                or otherwise; or (ii) ownership of more than fifty percent (50%) of
                the equity or other ownership interest of the entity.
                

            

    

    

    
      	 	
              b)

            	
              “Confidential
                Information” means all business, financial and technical information,
                data, documents and other materials, whether in electronic or physical
                form or orally disclosed, provided by one party (“Discloser”) to the other
                party (“Receiver”), but excluding any information that Receiver can
                demonstrate: 

            

    

    

    
      	 	
              (1)

            	
              was
                public knowledge at the time of disclosure to
                Receiver;

            

    

    

    
      	 	
              (2)

            	
              became
                public knowledge without fault by Receiver;

            

    

    

    
      	 	
              (3)

            	
              was
                rightfully in the possession of Receiver prior its disclosure by
                Discloser; or

            

    

    

    
      	 	
              (4)

            	
              was
                disclosed to Receiver on an unrestricted basis from a source not
                known to
                be under a duty of confidentiality to
                Discloser.

            

    

    

    
      	 	
              c)

            	
              “Dollars”
                or “$” mean U.S. Dollars.

            

    

    

    
      	 	
              d)

            	
              “Effective
                Date” means the date first noted
                above.

            

    

    

    
      	 	
              e)

            	
              “Invention”
                means any invention or discovery conceived, whether or not reduced
                to
                practice. 

            

    

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    
      	 	
              f)

            	
              “Joint
                Invention” means any Invention that is related to or covered by any Patent
                Right and was co-invented by at least one individual from TI and
                at least
                one individual from Licensee. 

            

    

    

    
      	 	
              g)

            	
              “Licensed
                Field” means all compositions, components, devices, systems and processes
                which use or apply to halloysite, halloysite microtubules or similar
                structures (“Halloysite Applications”), but excluding all Halloysite
                Applications for diagnosing, preventing, treating or curing diseases
                in
                humans or other animals.

            

    

    

    
      	 	
              h)

            	
              “Licensed
                Product” means any product, the manufacture, use, importation or sale of
                which is covered by a Valid Claim.

            

    

    

    
      	 	
              i)

            	
              “Licensee”
                means NaturalNano and/or its Affiliates, as the context may
                indicate.

            

    

    

    
      	 	
              j)

            	
              “Net
                Sales” means revenues from the sale, lease or other disposition of
                Licensed Products by a Licensee to a non-Licensee, less:
                

            

    

    

    
      	 	
              i)

            	
              payments
                made or credits allowed for promotional
                purposes;

            

    

    

    
      	 	
              ii)

            	
              customary
                allowances, rebates and trade, quantity, or cash discounts, to the
                extent
                allowed and taken; 

            

    

    

    
      	 	
              iii)

            	
              amounts
                repaid or credited for rejections or returns; and
                

            

    

    

    
      	 	
              iv)

            	
              to
                the extent separately stated on invoices, taxes and other governmental
                charges levied on the production, sale, transportation, delivery
                or use of
                a Licensed Product, paid by or on behalf of a
                Licensee.

            

    

    

    
      	 	
              k)

            	
              “Patent
                Rights” means: (i) the patent applications listed on Exhibit A;
                (ii) patents and patent applications owned or licensable by TI now or
                in the future and related to the Licensed Field; (iii) Joint Inventions;
                (iv) reissues, reexaminations, renewals, extensions, divisions,
                continuations, and continuations-in-part of (i), (ii) or (iii);
                (v) foreign counterparts of any of (i), (ii), (iii) and (iv); and
                (vi) patents which issue on any of (i), (ii), (iii), (iv) and
                (v).

            

    

    

    
      	 	
              l)

            	
              “Revenues”
                means all license fees, milestone payments, minimum royalties, running
                royalty revenues and other sums received by Licensee from Sublicenses,
                but
                excluding (i) revenues to support research and development efforts,
                (ii)
                reimbursements of out-of-pocket expenses, and (iii) payments for
                the
                purchase of securities of NaturalNano, priced on an arms’-length
                basis.

            

    

    

    
      	 	
              m)

            	
              “Sublicense”
                means any sublicense or other agreement of a Licensee permitting
                the
                commercial exploitation of any Patent Right(s) or Confidential Information
                by a third party.

            

    

    

    
      	 	
              n)

            	
              “Sublicensee”
                means the licensee of a Sublicense.

            

    

    

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    
      	 	
              o)

            	
              “Valid
                Claim” means: (i) a claim of an issued and unexpired patent of the
                Patent Rights which has not been disclaimed, or held invalid or
                unenforceable by an unappealed or unappealable decision of a court
                or
                governmental body, and (ii) one or more claims of a patent application
                being prosecuted in good faith, for two (2) years following the first
                commercial sale or use of a Licensed Product which is a Licensed
                Product
                solely because of the pending
                claim.

            

    

    

    
      	
              2)

            	
              License
                Grant.

            

    

    

    
      	 	
              a)

            	
              Termination
                of Prior Agreement.
                The Prior Agreement is hereby terminated and replaced by this
                Agreement.

            

    

    

    
      	 	
              b)

            	
              Grant
                to Licensee.
                TI grants to NaturalNano and its Affiliates the sole and exclusive,
                world-wide, royalty-bearing right and license under the Patent Rights
                and
                Confidential Information to develop, make, have made, use, sell,
                offer to
                sell and import Licensed Products in the Licensed Field only, including
                the rights to sue and collect damages for infringements prior to
                the date
                of this Agreement.

            

    

    

    
      	 	
              c)

            	
              Sublicenses.
                Licensee may grant Sublicenses, consistent with the applicable terms
                and
                conditions of this Agreement. Each Sublicense
                shall:

            

    

    

    
      	 	
              i)

            	
              require
                the Sublicensee to exercise reasonable diligence in developing,
                commercializing, marketing and selling Licensed Products;
                and

            

    

    

    
      	 	
              ii)

            	
              incorporate
                the substance of paragraphs 2(b)(i), 5, 6(a), 9, 10 and 12, mutatis
                mutandis.

            

    

    

    
      	 	
              d)

            	
              Grant-Back.
                NaturalNano
                grants to TI and its Affiliates a world-wide, royalty-bearing exclusive
                license with respect to all patent applications and patents owned
                or
                licensable by NaturalNano from TI during the term of this Agreement; provided,
                however that (i) NaturalNano retains an exclusive license with respect
                to
                the foregoing patents and patent applications for the Licensed Field
                and
                (ii) the royalty provisions of paragraphs 4 and 5 (and the related
                definitions) shall apply to any royalty-bearing sales by TI and its
                Affiliates, mutatis
                mutandis, except
                that all royalties payable by TI shall be one-half (1⁄2) of the amounts
                specified in paragraph 4.

            

    

    

    
      	
              3)

            	
              Cooperation
                and Sublicensing Activity.

            

    

    

    
      	 	
              a)

            	
              Diligence.
                NaturalNano will use reasonable diligence to develop, commercialize,
                market and sell Licensed Products, itself and/or through one or more
                Affiliates or Sublicensees.

            

    

    

    
      	 	
              b)

            	
              Cooperation.
                TI
                will make available to Licensee, from time-to-time, all information
                and
                materials in its possession, including Confidential Information,
                that is
                necessary or desirable to enable NaturalNano to develop, test and
                commercially introduce any Licensed
                Product.

            

    

    

    
      	 	
              c)

            	
              Commercialization
                Plan.
                NaturalNano will provide to TI a detailed, written annual research,
                development and commercialization plan for Licensed Products. The
                commercialization plan will include any plans for the Sublicensing
                of
                Patent Rights and Confidential Information.

            

    

    

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    
      	 	
              d)

            	
              No
                Challenges.
                TI shall not bring, authorize or assist a third party to bring any
                action
                under any other intellectual property now or in the future owned
                or
                licensed by any Licensee, to prevent a Licensee from exercising the
                rights
                granted by TI hereunder. TI shall impose this covenant on the assignees
                of
                any Patent Rights. 

            

    

    

    
      	
              4)

            	
              Compensation.

            

    

    

    
      	 	
              a)

            	
              Minimum
                Annual Royalties.
                Commencing with the quarter in which the first U.S. patent of Patent
                Rights is issued, NaturalNano shall pay to TI a minimum royalty of
                Six
                Thousand Two Hundred Fifty Dollars ($6,250) per calendar quarter.
                Each
                minimum royalty amount shall be credited only against royalties due
                in the
                calendar quarter for which the minimum royalty is
                payable.

            

    

    

    
      	 	
              b)

            	
              Royalties.
                NaturalNano shall pay TI a royalty
                of:

            

    

    

    
      	 	
              i)

            	
              Five
                percent (5%) of Net Sales by Licensees; and

            

    

    

    
      	 	
              ii)

            	
              Twenty
                Five percent (25%) of Revenues.

            

    

    

    
      	 	
              c)

            	
              Apportioning
                Royalties and Revenues.
                

            

    

    

    
      	 	
              i)

            	
              Royalties.
                If Licensee licenses from one or more third parties (“Third Parties”)
                intellectual property which also covers any Licensed Product, the
                royalty
                rate applied under paragraph 4(b)(i) as to Net Sales of that Licensed
                Product shall be (i) one (1) divided by (ii) one (1) plus the lesser
                of (a) the number of Third Parties to which royalties are payable
                as to
                that Licensed Product/Process, and (b) three (3); multiplied by (iii)
                Five
                percent (5%).

            

    

    

    
      	 	
              ii)

            	
              Revenues.
                If Licensee
                includes in any Sublicense intellectual property sublicensed from
                one or
                more Third Parties which covers any Licensed Product, the percentage
                of
                Revenues payable by NaturalNano under paragraph 4(b)(ii) as to that
                Licensed Product will be: (i) one (1) divided by (ii) one (1) plus
                the lesser of (a) the number of Third Parties to which royalties
                are
                payable as to that Licensed Product/Process, and (b) three (3); multiplied
                by (iii) twenty-five percent (25%).

            

    

    

    
      	 	
              iii)

            	
              Allocation.
                If:

            

    

    

    
      	 	
              (1)

            	
              Any
                lump sum Revenues under paragraph 4(b)(ii), such as up-front payments,
                milestone payments or minimum royalties, are not fairly allocated
                by use
                of the formula of paragraph 4(c)(ii), as where one lump sum payment
                covers
                products or fields of use that are covered by different groups of
                patents,
                those lump sum Revenues shall be allocated between TI and the Third
                Parties on a fair and reasonable basis;
                or

            

    

    

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    
      	 	
              (2)

            	
              There
                is uncertainty whether a particular patent(s) licensed by TI or a
                Third
                Party covers a Licensed Product for which a royalty is payable under
                paragraph 4(b)(i) or (ii);

            

    

    

    the
      dispute shall be resolved in accordance with paragraph 13.

    

    
      	 	
              d)

            	
              Payment
                Terms.
                

            

    

    

    
      	 	
              i)

            	
              Amounts
                due under paragraphs 4(a) and (b) are payable quarterly within forty-five
                (45) days after each calendar quarter.

            

    

    

    
      	 	
              ii)

            	
              If
                any amount due to TI is collected in a currency other than Dollars,
                the
                amount shall be converted into Dollars at the applicable exchange
                rate
                published in the Eastern edition of The
                Wall Street Journal
                on
                the last business day of the calendar quarter in which the collection
                was
                made. 

            

    

    

    
      	 	
              e)

            	
              Royalty
                Term.
                Royalties are payable for each Licensed Product on a country-by-country
                basis until expiration of the last-to-expire applicable Valid Claim
                in the
                country.

            

    

    

    
      	 	
              f)

            	
              Tax
                Withholding.
                If NaturalNano is required by the laws of any country to withhold
                any tax
                with respect to any payment to TI, the tax will be deducted and paid
                to
                the taxing authority. NaturalNano will notify TI and promptly furnish
                TI
                with original receipts of any tax certificate or other available
                documentation evidencing the tax withheld. NaturalNano will use
                commercially reasonable efforts to minimize any
                withholding.

            

    

    

    
      	
              5)

            	
              Reports
                and Records. 

            

    

    

    
      	 	
              a)

            	
              Royalty
                Reports.
                Each royalty payment under paragraph 4(b) shall be accompanied by
                a
                detailed royalty report, specifying the computation of royalties
                payable
                and certified to be correct by the Chief Financial Officer and President
                of Licensee. 

            

    

    

    
      	 	
              b)

            	
              Books
                and Records.
                Licensee shall keep accurate books of account adequate to show amounts
                payable under this Agreement and the performance of the Licensee’s other
                obligations hereunder for three (3) years after each applicable
                year.

            

    

    

    
      	 	
              c)

            	
              Audit
                Request.
                Licensee shall permit an independent, certified public accountant
                appointed and paid by TI to examine and make copies of applicable
                records
                and other documents no more often than once per calendar year for
                the
                purpose of verifying amounts and reports due from, and obligations
                to be
                performed by, the Licensee. The results of each examination shall
                be made
                available to TI and the Licensee, and shall be considered Confidential
                Information. Should the audit discover an underpayment equal to the
                greater of five percent (5%) or Twenty Five Thousand Dollars ($25,000),
                the applicable Licensee shall pay the cost of the
                audit.

            

    

    

    
      	 	
              i)

            	
              Late
                Charge.
                All overdue payments will be paid promptly with a late charge of
                two
                percent (2%) per annum above the prime rate of J.P. Morgan Chase
                Manhattan Bank, N.A., as reported in the Eastern edition of The
                Wall Street Journal
                on
                the last business day of the calendar quarter in which each payment
                was to
                be made. Interest is to be calculated from the last day on which
                the
                payment was payable.. 

            

    

    

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    
      	
              6)

            	
              Intellectual
                Property of Licensee. 

            

    

    

    
      	 	
              a)

            	
              Sublicensee
                Confidential Information and Patents. Each Sublicensee shall disclose
                and
                grant to NaturalNano and TI a non-exclusive, royalty-free world-wide
                license under all Sublicensee:

            

    

    

    
      	 	
              I)

            	
              Confidential
                Information; and 

            

    

    

    
      	 	
              II)

            	
              patents
                and patent applications; 

            

    

    

    that
      are
      owned or licensable by the Sublicensee and relate to the manufacture, use or
      sale of
      Licensed
      Products.

    

    
      	 	
              b)

            	
              Patent
                Costs.
                

            

    

    

    
      	 	
              i)

            	
              TI
                shall control the filing, prosecution and maintenance of Patent
                Rights.

            

    

    

    
      	 	
              ii)

            	
              TI
                shall provide patent counsel for NaturalNano with copies of all patent
                applications, Office Actions and other prosecution documents in connection
                with Patent Rights and enable NaturalNano’s patent counsel to meet and
                confer with TI’s patent counsel in connection with Patent Rights, at least
                thirty (30) days before (A) filing any new U.S. or foreign application,
                (B) payment of any issue or maintenance fees or (C) filing any response
                to
                a U.S. or foreign Office Action. 

            

    

    

    
      	 	
              iii)

            	
              Subject
                to subparagraph 6(b)(iv), NaturalNano shall reimburse TI for all
                reasonable legal fees and out-of-pocket costs incurred by TI after
                April
                27, 2005, for the filing, prosecution, and maintenance of Patent
                Rights.

            

    

    

    
      	 	
              iv)

            	
              TI
                shall promptly notify NaturalNano of any fees payable in connection
                with
                the Patent Rights. NaturalNano may elect not to pay any such fees,
                in
                which case the applicable patent or patent application shall thereafter
                not be part of the Patent Rights. 

            

    

    

    
      	 	
              c)

            	
              Joint
                Inventions.
                This Agreement constitutes, in part, a "joint research agreement"
                between
                Licensors and Licensee, as defined in the CREATE Act, 35 U.S.C. § 103(c),
                under which Licensee will carry out some of its obligations pursuant
                to
                paragraph 3. Intellectual property developed in the Licensed Field
                and any other technologies that are within the scope of the Patent
                Rights will be deemed made as a result of activities undertaken within
                the
                scope of the joint research agreement and subject to the CREATE
                Act.

            

    

    

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

    
      	
              7)

            	
              Infringement.

            

    

    

    
      	 	
              a)

            	
              Notices.
                Each party shall inform the other promptly of any third party infringement
                of Patent Rights or misappropriation of Confidential Information
                of which
                it has knowledge.

            

    

    

    
      	 	
              b)

            	
              Enforcement.
                

            

    

    

    
      	 	
              i)

            	
              If
                any Patent Rights are infringed by products or processes in the Licensed
                Field, NaturalNano, after consultation with TI, shall have the right,
                but
                not the obligation, to bring a patent infringement suit and may join
                TI in
                the suit, all at NaturalNano's expense.

            

    

    

    
      	 	
              ii)

            	
              If
                the Patent Rights are infringed by products or processes in and outside
                the Licensed Field, NaturalNano shall, if requested by TI, include
                the
                claims for infringement outside the Licensed Field in any suit it
                brings,
                but only if the parties shall have agreed in writing on a basis for
                allocating damages awarded or license or settlement payments between
                infringements in and outside of the Licensed Field.
                

            

    

    

    
      	 	
              iii)

            	
              NaturalNano’s
                rights include the right to sue for and collect damages for past
                infringements of Patent Rights in the Licensed Field and, if requested
                by
                TI, shall include infringements outside the Licensed Field.
                

            

    

    

    
      	 	
              c)

            	
              Declaratory
                Judgment Suits.
                If a declaratory judgment suit is brought against any Licensee, alleging
                invalidity, unenforceability, or non-infringement of any Patent Rights,
                the Licensee shall provide prompt notice thereof to TI; and TI, at
                its
                option, shall have the right, but not the obligation, within thirty
                (30)
                days after commencement of the suit, to assume the defense of the
                suit at
                its expense.

            

    

    

    
      	 	
              d)

            	
              Cooperation.
                In
                connection with any litigation involving the Patent Rights or Confidential
                Information, TI shall make its then-present and former employees
                and
                consultants available to NaturalNano, subject to payment of reasonable
                fees for their time and reimbursement of out-of-pocket
                expenses.

            

    

    

    
      	 	
              e)

            	
              Recovery.
                Any amount received as an award in or a license or settlement agreement
                entered into pursuant to any claim or suit under paragraph 7(b) shall
                be
                distributed as follows:

            

    

    

    
      	 	
              i)

            	
              First,
                to reimburse the parties, pro
                rata,
                for their out-of-pocket legal fees and expenses incurred in connection
                with the claim or suit; and

            

    

    

    
      	
            	ii)	
              Unless
                otherwise agreed in writing by the parties, the balance shall be
                paid:

            

    

    

    
      	 	
              (1)

            	
              Seventy
                five percent (75%) to NaturalNano;
                and

            

    

    

    
      	 	
              (2)

            	
              Twenty-five
                percent (25%) to TI;

            

    

    

    Payments
      shall be made within thirty (30) days after funds are received and shall be
      accompanied by a report detailing the computation of the payments.

    

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

    
      	
              8)

            	
              Representations
                and Warranties.
                TI
                represents and warrants to NaturalNano
                that:

            

    

    

    
      	 	
              a)

            	
              Right
                and Power.
                TI
                has the right and power to enter into and perform this Agreement
                in
                accordance with its terms.

            

    

    

    
      	 	
              b)

            	
              Ownership.
                TI owns all right, title and interest in and to the Patent Rights
                and the
                Confidential Information, free and clear of liens, security interests,
                charges and other encumbrances. No Patent Right has been abandoned.
                

            

    

    

    
      	 	
              c)

            	
              No
                Other License.
                TI has not granted any other license or covenant not to sue with
                respect
                to any of the Patent Rights or Confidential Information, except for
                the
                Prior License. 

            

    

    

    
      	 	
              d)

            	
              No
                Infringements.
                To TI’s knowledge, with no investigation having been made or required to
                be made, Licensee’s practice of the Patent Rights and Confidential
                Information will not infringe any patent or other right of any third
                party. 

            

    

    

    
      	 	
              e)

            	
              Validity.
                To TI's knowledge, with no investigation having been made or required
                to
                be made, the Patent Rights are valid and enforceable.
                

            

    

    

    
      	 	
              f)

            	
              Agreements
                with Inventors of Patent Rights.
                TI
                has contracts with all inventors of Patent Rights requiring them,
                during
                and after their employment or other engagement by TI, to cooperate
                fully,
                if requested, in all prosecution or litigation of Patent Rights,
                subject
                only to payment of reasonable fees for their time and reimbursement
                of
                out-of-pocket expenses.

            

    

    

    
      	 	
              g)

            	
              Third
                Person Payments.
                Except for amounts due under paragraph 4, no statutory or other
                amount is or will be owed to any other person in connection with
                any
                Patent Right(s), or Confidential
                Information.

            

    

    

    
      	 	
              h)

            	
              No
                Claims.
                No claim has been asserted or threatened by any third-party alleging
                that
                (i) any of the Patent Rights is invalid or unenforceable, or
                (ii) the development, manufacture, use or sale of Licensed Products
                infringes the rights of any third
                person.

            

    

    

    
      	 	
              i)

            	
              No
                Other Warranties.
                Except as set forth in paragraphs 8(a) to (h), TI makes no other
                representations or warranties whatsoever, and there is no warranty
                of
                merchantability or fitness for a particular
                purpose.

            

    

    

    
      	
              9)

            	
              Indemnification;
                Insurance.

            

    

    

    
      	 	
              a)

            	
              Indemnity.
                Any Licensee that manufactures or sells a Licensed Product, shall
                indemnify, defend, and hold harmless TI and its Affiliates, officers,
                employees, agents, successors, and assigns (the "Indemnitees"), against
                any claim, demand, liability or expense (including reasonable attorneys’
                fees and expenses, whether incurred as the result of a third party
                claim
                or a claim to enforce this provision) incurred by or imposed upon
                any of
                the Indemnitees in connection with any third party claims, suits,
                or
                judgments arising out of any theory of liability (including tort,
                warranty, or strict liability suits or claims and whether or not
                such suit
                or claim has a factual basis) concerning any Licensed Product
                (collectively, “Claims”), except to the extent that the damages claimed
                were caused by TI or anyone under its direction or
                control.

            

    

    

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

    
      	 	
              b)

            	
              Procedure.
                The Indemnitees shall provide NaturalNano with prompt written notice
                of
                each Claim for which indemnification is sought. NaturalNano, at its
                expense, shall defend any such Claim. The Indemnitees shall cooperate
                fully in such defense and permit NaturalNano to conduct and control
                the
                defense and the disposition of the Claim (including all decisions
                relative
                to appeal, and settlement); provided, however, that any Indemnitee
                shall
                have the right to retain its own counsel, at the Indemnitee’s expense.
                NaturalNano shall keep TI informed of the progress in the defense
                and
                disposition of any Claim and shall consult with TI with regard to
                any
                proposed settlement. NaturalNano shall obtain the written consent
                of TI to
                any settlement which would adversely affect
                TI.

            

    

    

    
      	 	
              c)

            	
              Insurance.
                

            

    

    

    
      	 	
              i)

            	
              Each
                Licensee that manufactures and/or sells Licensed Products shall maintain
                in full force and effect at all times during the term of this Agreement
                with a reputable commercial insurance carrier, commercial general
                liability insurance of a
                type as may be necessary to protect their interests and fulfill its
                obligations under this Agreement, including without limitation contractual
                liability insurance,
                covering the marketing, sale, distribution, use and performance of
                Licensed Products
                in
                an amount of at least Two
                Million Dollars ($2,000,000)
                per occurrence and Two Million Dollars ($2,000,000) in the
                aggregate.
                

            

    

    

    
      	 	
              ii)

            	
              The
                insurance of subparagraph (i) shall be issued by an insurer licensed
                to practice in, as to Licensee, the State of New York and otherwise
                in the
                State(s) in which the applicable Licensee undertakes activities in
                connection with the exercise of its rights, or an insurer pre-approved
                by
                TI, such approval not to be unreasonably withheld; (ii) shall be
                endorsed to include product liability coverage; and (iii) shall
                require thirty (30) days’ written notice to TI before any cancellation or
                material change. 

            

    

    

    
      	 	
              iii)

            	
              Licensee
                shall, upon request, provide TI with a Certificate of Insurance and
                the
                underlying policy(ies) evidencing compliance with this paragraph
                9(c).
                

            

    

    

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

    
      	
              10)

            	
              Confidential
                Information.
                During
                the term of this Agreement and for three (3) years thereafter, each
                Receiver will:

            

    

    

    
      	 	
              a)

            	
              use
                commercially reasonable efforts, but no less than the protection
                given to
                its own confidential information, to maintain in confidence all
                Confidential Information, including without limitation the financial
                terms
                of this Agreement; 

            

    

    

    
      	 	
              b)

            	
              Disclose
                Confidential Information only:

            

    

    

    
      	 	
              I)

            	
              to
                the Receiver’s employees, consultants and legal, financial and business
                advisors who reasonably need to know such information for the Receiver
                to
                perform its obligations or otherwise conduct its activities hereunder;
                or

            

    

    

    
      	 	
              II)

            	
              As
                required by court order,
                statute,
                governmental regulation or securities exchange rule, upon at least
                thirty
                (30) days prior notice to TI.

            

    

    

    
      	
              11)

            	
              Termination.

            

    

    

    
      	 	
              a)

            	
              Termination
                by TI.
                TI may terminate this Agreement and the rights granted hereunder
                to
                Licensee if:

            

    

    

    
      	 	
              i)

            	
              Licensee
                breaches any material provision of this Agreement and has not cured
                the
                breach within thirty (30) days after notice from TI specifying the
                nature
                of the breach in reasonable detail;
                or

            

    

    

    
      	 	
              ii)

            	
              Licensee
                or any Sublicensees do not achieve a commercial roll-out of the sale
                of a
                Licensed Product within three (3) years from the Effective Date;
                or
                

            

    

    

    
      	 	
              iii)

            	
              NaturalNano
                does not pay TI annual sums under paragraphs 4(a) and (b) of at least
                Twenty Five Thousand Dollars ($25,000) for calendar year 2009 and
                at least
                Fifty Thousand Dollars ($50,000) per calendar year thereafter; or
                

            

    

    

    
      	 	
              iv)

            	
              NaturalNano
                generally ceases to conduct
                business.

            

    

    

    
      	 	
              b)

            	
              Termination
                by NaturalNano.
                NaturalNano may terminate this Agreement with or without cause, on
                thirty
                (30) days’ written notice to TI.

            

    

    

    
      	 	
              c)

            	
              Bankruptcy.
                All rights and licenses granted under or pursuant to this Agreement
                by TI
                to the Licensees are, for all purposes of paragraph 365(n) of
                Title 11 of the United States Code (“Title 11”) or other
                relevant bankruptcy or insolvency law (collectively, “Law”), licenses of
                rights to “intellectual property” as defined in Title 11 or such
                other Law. 

            

    

    

    
      	 	
              d)

            	
              Effects
                of Termination.
                

            

    

    

    
      	 	
              i)

            	
              Nothing
                herein will release any party from any obligation that matured prior
                to
                the effective date of any termination of this Agreement. Subject
                to the
                foregoing, paragraphs 2(d), 5, 6, 9, 10 and 13 will survive termination
                of
                this Agreement. 

            

    

    

    
      
         

      

      
        10

        
          

        

      

      
         

      

    

    
      	 	
              ii)

            	
              Each
                Licensee may, after termination, sell all Licensed Products then
                in
                inventory or work-in-process, provided the Licensee makes the applicable
                payments under paragraph 4(b). 

            

    

    

    
      	 	
              iii)

            	
              All
                Sublicenses shall remain in full force and effect after termination
                of
                this Agreement for any reason; and NaturalNano or the Sublicensee,
                shall
                make all payments to TI with respect to Revenues that NaturalNano
                would
                otherwise have been obligated to make
                hereunder.

            

    

    

    
      	 	
              e)

            	
              Return
                of Information.
                Upon termination of this Agreement, each Receiver will return all
                applicable Confidential Information supplied to Receiver, except
                that
                Receiver’s counsel may keep one archival
                copy.

            

    

    

    
      	
              12)

            	
              General
                Compliance with Laws.

            

    

    

    
      	 	
              a)

            	
              Compliance
                with Laws.
                TI shall comply with all local, state, federal, and international
                laws and
                regulations relating to its performance under this Agreement, including
                but not limited to the development, manufacture, use, and sale of
                any
                Licensed Product, including export control laws. Without limiting
                the
                generality of this paragraph, NaturalNano shall be responsible for
                the
                preparation and submission of all applications relating to any required
                regulatory approval of any Licensed Product, whether by the FDA or
                other
                regulatory body.

            

    

    

    
      	 	
              b)

            	
              Marking.
                Each Licensee shall mark all Licensed Products with the number of
                each
                applicable patent of the Patent Rights. NaturalNano shall provide
                Licensor
                with written notice of compliance with this paragraph by December
                31 of
                each year.

            

    

    

    
      	13)	
              Arbitration
                of Disputes.
                Any dispute under this Agreement shall be resolved by an arbitration
                proceeding conducted in Rochester, NY under the then-prevailing Rules
                for
                Commercial Arbitration and the Patent Arbitration Rules, as applicable,
                of
                the American Arbitration Association (“AAA”).

            

    

    

    
      	 	
              a.

            	
              The
                proceeding shall be conducted by one (1) arbitrator, reasonably acceptable
                to the parties, who is a patent attorney with at least twenty (20)
                years
                of experience, of which ten (10) years or more have been spent (at
                least
                in substantial part) handling licensing transactions.
                

            

    

    

    
      	 	
              b.

            	
              The
                fees of the mediator and the AAA shall be divided equally between
                the
                parties.

            

    

    

    
      	 	
              c.

            	
              The
                parties shall cooperate in good faith to proceed to an arbitration
                hearing
                within six (6) months after the Demand for Arbitration shall have
                been
                filed with the AAA. 

            

    

    

    
      	 	
              d.

            	
              The
                arbitrator’s authority shall include the powers, in his/her discretion,
                to: 

            

    

    

    
      	 	
              i.

            	
              Expedite
                the proceeding;

            

    

    

    
      
         

      

      
        11

        
          

        

      

      
         

      

    

    
      	 	
              ii.

            	
              Permit
                limited discovery, including production of documents and depositions,
                to
                the extent required by the parties; and

            

    

    

    
      	 	
              iii.

            	
              Award
                the prevailing party its attorneys’ fees and out-of-pocket expenses,
                including its share of the mediator and AAA fees.
                

            

    

    

    
      	 	
              e.

            	
              The
                decision of the arbitrator shall be confidential, final and binding,
                and
                may be entered and enforced in any court of competent jurisdiction.
                

            

    

    

    14)
      Miscellaneous.

    

    a.
      Notices.
      Any
      notices required or permitted by this Agreement shall be in writing and
      personally delivered or sent by prepaid express courier service, signature
      requested. Notices shall be effective upon receipt. Notices shall be sent to
      the
      addresses of the parties specified on the first page of this Agreement or such
      other address as given by proper notice. 

    

    b.
      Governing Laws.
      This
      Agreement will be governed by and construed in accordance with New York law,
      without reference to conflicts of laws principles. 

    

    c.
      Entire Agreement.
      This
      Agreement contains the entire agreement of the parties with respect to its
      subject matter, and supersedes all previous agreements and understandings,
      written or oral, express or implied. This Agreement may only be amended by
      a
      writing signed by the parties. 

    

    d.
      Successors and Assigns.
      This
      Agreement is binding upon the parties and their successors and permitted
      assigns. Neither party may assign its rights or obligations hereunder without
      the prior written consent of the other, except that NaturalNano may assign
      this
      Agreement in connection with its merger or the acquisition of all or
      substantially all of the assets to which this Agreement relates.

    

    e.
      Counterparts.
      This
      Agreement may be signed in two or more counterparts, each of which will be
      deemed an original, but all of which together will constitute one and the same
      instrument.

    

    f.
      Headings.
      The
      headings contained in this Agreement are for reference purposes only and will
      not affect in any way the meaning or interpretation of this
      Agreement.

    

    
      
         

      

      
        12

        
          

        

      

      
         

      

    

    In
      witness whereof,
      the
      parties have executed this Agreement by their duly authorized
      representatives.

    

    

    Technology
      Innovations, LLC

    

    

    By
                /s/ Michael
      Weiner        
                     

    Michael
      Weiner, CEO

    

    NaturalNano,
      Inc.

    

    By          
      /s/ Michael
      Riedlinger                         

    Michael
      Riedlinger, President

    
      
         

      

      
        13

        
          

        

      

      
         

      

    

    EXHIBIT
      A

    

    
      	
              BI
                Reference Number

            	
              Filing
                Date

            
	
              1034312-000015

            	
              Oct.
                6, 2005

            
	
              1034312-000016

            	
              Oct.
                7, 2005

            
	
              1034312-000032

            	
              Jan.
                25, 2005

            
	
              1034312-000033

            	
              May
                20, 2005

            
	
              1034312-000036

            	
              July
                18, 2005

            
	
              1034312-000038

            	
              April
                5, 2005

            

    

    

    

    
      
         

      

      
        14THIS WARRANT AND THE SHARES OF COMMON STOCK  ISSUABLE UPON EXERCISE  HEREOF HAVE
NOT  BEEN  REGISTERED  UNDER  THE  SECURITIES  ACT  OF  1933,  AS  AMENDED  (THE
"SECURITIES ACT") OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD,  TRANSFERRED
OR OTHERWISE  DISPOSED OF UNLESS  REGISTERED  UNDER THE SECURITIES ACT AND UNDER
APPLICABLE  STATE SECURITIES LAWS OR MEDICAL MEDIA  TELEVISION,  INC. SHALL HAVE
RECEIVED  AN  OPINION  OF  COUNSEL  REASONABLY  SATISFACTORY  TO  MEDICAL  MEDIA
TELEVISION,  INC. THAT  REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT
AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.

                               WARRANT TO PURCHASE

                             SHARES OF COMMON STOCK

                                       OF

                         MEDICAL MEDIA TELEVISION, INC.

                             Expires March 30, 2011

                                                        Number of Shares: 25,000
                                                                      ----------
Date of Issuance: March 31, 2006                        Warrant No.:     W-E0331

         FOR VALUE  RECEIVED,  subject to the provisions  hereinafter set forth,
the undersigned, Medical Media Television, Inc., a Florida corporation (together
with its successors and assigns, the "Issuer"),  hereby certifies that Elaine G.
Edinburg,  a resident of  Colorado  (or her  registered  assigns) is entitled to
subscribe  for  and  purchase,   during  the  Term  (as  hereinafter   defined),
Twenty-five  Thousand  (25,000)  shares  (subject to adjustment  as  hereinafter
provided) of the duly authorized,  validly issued, fully paid and non-assessable
Common  Stock of the  Issuer,  at an exercise  price per share of $.75  subject,
however,  to the provisions and upon the terms and  conditions  hereinafter  set
forth.  Capitalized  terms used in this Warrant and not otherwise defined herein
shall have the respective meanings specified in Section 9 hereof.

         1. Term.  The term of this Warrant shall commence on March 31, 2006 and
shall expire at 5:00 p.m.,  Eastern  Time,  on March 30, 2011 (such period being
the "Term").

         2. Method of Exercise  Payment;  Issuance of New Warrant;  Transfer and
Exchange.

         (a) Time of Exercise.  The purchase rights  represented by this Warrant
may be  exercised  in whole or in part during the Term  commencing  on March 31,
2006 and expiring on March 30, 2011.

         (b) Method of Exercise. The Holder hereof may exercise this Warrant, in
whole or in part,  by the  surrender  of this Warrant  (with the  exercise  form
attached hereto duly executed) at the principal office of the Issuer, and by the
payment  to the  Issuer  of an  amount of  consideration  therefor  equal to the
Warrant Price,  payable at such Holder's  election by certified or official bank
check or by wire transfer to an account designated by the Issuer.

         (c) Issuance of Stock Certificates. In the event of any exercise of the
rights  represented by this Warrant in accordance  with and subject to the terms
and  conditions  hereof,  (i)  certificates  for the shares of Warrant  Stock so
purchased  shall be dated the date of such  exercise and delivered to the Holder
hereof within a reasonable time, not exceeding three (3) Trading Days after such
exercise and the Holder hereof shall be deemed for all purposes to be the holder
of the shares of Warrant Stock so purchased as of the date of such exercise and,
unless this Warrant has expired, a new Warrant representing the number of shares
of Warrant Stock, if any, with respect to which this Warrant shall not then have
been exercised shall also be issued to the Holder hereof at the Issuer's expense
within such time.

<PAGE>

        (d)  Transferability  of Warrant.  Subject to provisions  herein,  this
Warrant may be  transferred  by a Holder  without the consent of the Issuer.  If
transferred  pursuant  to  this  paragraph  and  subject  to the  provisions  of
subsection  (f) of this Section 2, this Warrant may be  transferred on the books
of the Issuer by the  Holder  hereof in person or by duly  authorized  attorney,
upon surrender of this Warrant at the principal  office of the Issuer,  properly
endorsed (by the Holder executing an assignment in the form attached hereto) and
upon payment of any necessary transfer tax or other governmental  charge imposed
upon such transfer.  This Warrant is exchangeable at the principal office of the
Issuer for Warrants for the purchase of the same  aggregate  number of shares of
Warrant  Stock,  each new Warrant to represent the right to purchase such number
of shares of Warrant Stock as the Holder  hereof shall  designate at the time of
such exchange.  All Warrants  issued on transfers or exchanges shall be dated as
of the Original Issue Date and shall be identical with this Warrant except as to
the name of the Holder or the number of shares of Warrant Stock, as applicable.

         (e) Continuing Rights of Holder.  The Issuer will, at the time of or at
any time after each  exercise  of this  Warrant,  upon the request of the Holder
hereof,  acknowledge in writing the extent, if any, of its continuing obligation
to afford to such  Holder all rights to which such Holder  shall  continue to be
entitled  after such  exercise  in  accordance  with the terms of this  Warrant,
provided  that if any such  Holder  shall  fail to make any  such  request,  the
failure shall not affect the continuing  obligation of the Issuer to afford such
rights to such Holder.

         (f) Compliance with Securities Laws.

                  (i)  The  Holder  of  this  Warrant,   by  acceptance  hereof,
         acknowledges  that this  Warrant or the  shares of Warrant  Stock to be
         issued upon exercise  hereof are being acquired solely for the Holder's
         own  account  and  not as a  nominee  for  any  other  party,  and  for
         investment,  and that the  Holder  will not  offer,  sell or  otherwise
         dispose of this  Warrant  or any  shares of Warrant  Stock to be issued
         upon  exercise  hereof  except  pursuant to an  effective  registration
         statement, or an exemption from registration,  under the Securities Act
         and any applicable state securities laws.

                  (ii) Except as provided in paragraph (iii) below, this Warrant
         and all certificates  representing  shares of Warrant Stock issued upon
         exercise  hereof  shall  be  stamped  or  imprinted  with a  legend  in
         substantially the following form:

                  THIS  WARRANT  AND THE SHARES OF COMMON  STOCK  ISSUABLE  UPON
                  EXERCISE HEREOF HAVE NOT BEEN REGISTERED  UNDER THE SECURITIES
                  ACT OF 1933,  AS AMENDED (THE  "SECURITIES  ACT") OR ANY STATE
                  SECURITIES LAWS AND MAY NOT BE SOLD,  TRANSFERRED OR OTHERWISE
                  DISPOSED OF UNLESS  REGISTERED  UNDER THE  SECURITIES  ACT AND
                  UNDER  APPLICABLE  STATE  SECURITIES  LAWS  OR  MEDICAL  MEDIA
                  TELEVISION,  INC.  SHALL HAVE  RECEIVED  AN OPINION OF COUNSEL
                  REASONABLY SATISFACTORY TO MEDICAL MEDIA TELEVISION, INC. THAT
                  REGISTRATION OF SUCH  SECURITIES  UNDER THE SECURITIES ACT AND
                  UNDER THE PROVISIONS OF APPLICABLE  STATE  SECURITIES  LAWS IS
                  NOT REQUIRED.

                                       2
<PAGE>

                  (iii)  The   Issuer   agrees  to  reissue   this   Warrant  or
         certificates  representing any of the Warrant Stock, without the legend
         set forth  above if at such time,  prior to making any  transfer of any
         such  securities,  the Holder shall give  written  notice to the Issuer
         describing  the manner and terms of such  transfer  and  removal as the
         Issuer may reasonably request.  Such proposed transfer and removal will
         not be  effected  until:  (a) either (i) the  Issuer  has  received  an
         opinion of counsel reasonably satisfactory to the Issuer, to the effect
         that the  registration of such  securities  under the Securities Act is
         not  required  in  connection  with  such  proposed  transfer,  (ii)  a
         registration  statement under the Securities Act covering such proposed
         disposition  has been  filed by the  Issuer  with  the  Securities  and
         Exchange  Commission and has become effective under the Securities Act,
         (iii) the Issuer has received other evidence reasonably satisfactory to
         the  Issuer  that  such  registration  and   qualification   under  the
         Securities Act and state securities laws are not required,  or (iv) the
         Holder  provides  the  Issuer  with  reasonable  assurances  that  such
         security can be sold pursuant to Rule 144 under the Securities Act; and
         (b) either (i) the Issuer has received an opinion of counsel reasonably
         satisfactory  to  the  Issuer,  to  the  effect  that  registration  or
         qualification  under the  securities or "blue sky" laws of any state is
         not required in  connection  with such  proposed  disposition,  or (ii)
         compliance with applicable state securities or "blue sky" laws has been
         effected or a valid exemption exists with respect  thereto.  The Issuer
         will respond to any such notice from a holder  within five (5) business
         days.  In the case of any proposed  transfer  under this  Section,  the
         Issuer will use reasonable  efforts to comply with any such  applicable
         state securities or "blue sky" laws, but shall in no event be required,
         (x) to  qualify  to do  business  in any  state  where  it is not  then
         qualified,  (y) to take any action  that would  subject it to tax or to
         the  general  service  of  process  in any  state  where it is not then
         subject,  or (z) to comply with state  securities or "blue sky" laws of
         any state for which  registration by coordination is unavailable to the
         Issuer. The restrictions on transfer contained in this Section shall be
         in addition to, and not by way of limitation of, any other restrictions
         on transfer contained in any other section of this Warrant.

         (g) In no event may the  Holder  exercise  this  Warrant in whole or in
part unless the Holder is an  "accredited  investor" as defined in  Regulation D
under the Securities Act.

         3. Stock Fully Paid; Reservation and Listing of Shares; Covenants.

         (a) Stock Fully Paid. The Issuer  represents,  warrants,  covenants and
agrees that all shares of Warrant Stock which may be issued upon the exercise of
this Warrant or otherwise  hereunder  will,  when issued in accordance  with the
terms of this  Warrant,  be duly  authorized,  validly  issued,  fully  paid and
non-assessable  and free from all taxes, liens and charges created by or through
Issuer.  The Issuer  further  covenants and agrees that during the period within
which  this  Warrant  may be  exercised,  the  Issuer  will  at all  times  have
authorized  and  reserved  for the  purpose of the issue upon  exercise  of this
Warrant  a  sufficient  number of shares  of  Common  Stock to  provide  for the
exercise of this Warrant.

         (b) Reservation.  If any shares of Common Stock required to be reserved
for issuance  upon exercise of this Warrant or as otherwise  provided  hereunder
require registration or qualification with any governmental  authority under any
federal or state law before  such  shares may be so issued,  the Issuer  will in
good faith use its reasonable best efforts as  expeditiously  as possible at its
expense to cause such shares to be duly  registered or qualified.  If the Issuer
shall list any shares of Common  Stock on any  securities  exchange or market it
will, at its expense,  list thereon,  maintain and increase when  necessary such
listing,  of all shares of Warrant  Stock from time to time issued upon exercise
of this Warrant or as otherwise provided  hereunder  (provided that such Warrant
Stock  has been  registered  pursuant  to a  registration  statement  under  the
Securities  Act then in  effect),  and,  to the  extent  permissible  under  the
applicable securities exchange rules, all unissued shares of Warrant Stock which
are at any time issuable hereunder,  so long as any shares of Common Stock shall
be so  listed.  The  Issuer  will also so list on each  securities  exchange  or
market, and will maintain such listing of, any other securities which the Holder
of this  Warrant  shall be entitled to receive upon the exercise of this Warrant
if at the time  any  securities  of the  same  class  shall  be  listed  on such
securities exchange or market by the Issuer.

                                       3
<PAGE>

         (c) Covenants.  The Issuer shall not by any action  including,  without
limitation, amending the Articles of Incorporation or the by-laws of the Issuer,
or  through  any  reorganization,  transfer  of assets,  consolidation,  merger,
dissolution,  issue or sale of securities or any other action,  avoid or seek to
avoid the  observance or  performance  of any of the terms of this Warrant,  but
will at all times in good faith assist in the carrying out of all such terms and
in the taking of all such actions as may be necessary or  appropriate to protect
the rights of the Holder  hereof  against  dilution (to the extent  specifically
provided  herein)  or  impairment.   Without  limiting  the  generality  of  the
foregoing,  the Issuer will (i) not permit the par value,  if any, of its Common
Stock to exceed the then effective  Warrant Price,  (ii) not amend or modify any
provision  of the  Articles  of  Incorporation  or  by-laws of the Issuer in any
manner that would adversely  affect the rights of the Holders of the Warrants in
their capacity as Holders of the Warrants,  (iii) take all such action as may be
reasonably  necessary  in order that the Issuer may validly  and  legally  issue
fully  paid and  nonassessable  shares  of Common  Stock,  free and clear of any
liens,  claims,  encumbrances and  restrictions  (other than as provided herein)
upon the exercise of this Warrant,  and (iv) use its reasonable  best efforts to
obtain  all  such  authorizations,   exemptions  or  consents  from  any  public
regulatory body having  jurisdiction  thereof as may be reasonably  necessary to
enable the Issuer to perform its obligations under this Warrant.

         (d) Loss,  Theft,  Destruction  of  Warrants.  Upon receipt of evidence
satisfactory to the Issuer of the ownership of and the loss, theft,  destruction
or  mutilation  of any  Warrant  and,  in the  case of any such  loss,  theft or
destruction,  upon receipt of indemnity or security  satisfactory  to the Issuer
or, in the case of any such mutilation,  upon surrender and cancellation of such
Warrant,  the  Issuer  will  make and  deliver,  in lieu of such  lost,  stolen,
destroyed or mutilated Warrant, a new Warrant of like tenor and representing the
right to purchase the same number of shares of Common Stock.

         4. Adjustment of Warrant Price and Warrant Share Number.  The number of
shares of Common Stock for which this Warrant is  exercisable,  and the price at
which such  shares may be  purchased  upon  exercise of this  Warrant,  shall be
subject  to  adjustment  from time to time as set forth in this  Section  4. The
Issuer shall give the Holder notice of any event  described below which requires
an adjustment pursuant to this Section 4 in accordance with Section 5.

         (a) Recapitalization,  Reorganization, Reclassification, Consolidation,
Merger or Sale.

                  (i) In case the Issuer after the Original  Issue Date shall do
         any of the following (each, a "Triggering  Event"):  (a) consolidate or
         merge with or into another corporation where the holders of outstanding
         Voting Stock prior to such merger or  consolidation do not own over 50%
         of the outstanding  Voting Stock of the merged or  consolidated  entity
         immediately  after  such  merger or  consolidation,  or (b) sell all or
         substantially  all of its properties or assets to any other Person,  or
         (c) change the Common Stock to the same or  different  number of shares
         of  any  class  or  classes  of  stock,  whether  by  reclassification,
         exchange, substitution or otherwise (other than by way of a stock split
         or combination of shares or stock dividends or  distributions  provided
         for in  Section  4(b)  or  Section  4(c)),  or  (d)  effect  a  capital
         reorganization  (other than by way of a stock split or  combination  of
         shares or stock dividends or distributions provided for in Section 4(b)
         or Section 4(c)),  then, and in the case of each such Triggering Event,
         proper  provision  shall be made so that,  upon the basis and the terms
         and in the manner provided in this Warrant,  the Holder of this Warrant
         shall be  entitled  upon the  exercise  hereof  at any time  after  the
         consummation  of such  Triggering  Event, to the extent this Warrant is
         not exercised prior to such Triggering Event, to receive at the Warrant
         Price in effect at the time  immediately  prior to the  consummation of
         such  Triggering  Event in lieu of the Common Stock  issuable upon such
         exercise  of  this  Warrant  prior  to  such  Triggering   Event,   the
         securities,  cash and  property  to which such  Holder  would have been
         entitled upon the  consummation of such Triggering Event if such Holder
         had exercised the rights represented by this Warrant  immediately prior
         thereto,  subject to adjustments  (subsequent to such corporate action)
         as nearly  equivalent  as  possible  to the  adjustments  provided  for
         elsewhere in this Section 4.

                                       4
<PAGE>

                  (ii) Notwithstanding anything contained in this Warrant to the
         contrary,  a Triggering  Event shall not be deemed to have occurred if,
         prior to the consummation  thereof, each Person (other than the Issuer)
         which may be required to deliver any securities,  cash or property upon
         the  exercise  of this  Warrant as provided  herein  shall  assume,  by
         written  instrument  delivered to, and reasonably  satisfactory to, the
         Holder of this Warrant,  (A) the  obligations  of the Issuer under this
         Warrant  (and if the Issuer  shall  survive  the  consummation  of such
         Triggering  Event,  such assumption  shall be in addition to, and shall
         not release the Issuer from, any  continuing  obligations of the Issuer
         under this  Warrant) and (B) the  obligation  to deliver to such Holder
         such shares of securities,  cash or property as, in accordance with the
         foregoing  provisions  of this  subsection  (a),  such Holder  shall be
         entitled to receive,  and such Person shall have similarly delivered to
         such  Holder a written  acknowledgement  executed by the  President  or
         Chief Financial Officer of the Company, stating that this Warrant shall
         thereafter  continue  in full  force and  effect  and the terms  hereof
         (including,   without  limitation,   all  of  the  provisions  of  this
         subsection (a)) shall be applicable to the securities, cash or property
         which such Person may be required to deliver  upon any exercise of this
         Warrant or the exercise of any rights pursuant hereto.

         (b) Adjustments  for Issuance of Additional  Shares of Common Stock. In
the event the Company,  shall, at any time, from time to time, issue or sell any
additional shares of Common Stock or securities convertible into or exchangeable
for shares of Common Stock to a third party for a  consideration  per share less
than the Conversion  Price of the Note then in effect  immediately  prior to the
time of such issue or sale,  then,  forthwith  upon such  issuance or sale,  the
Conversion  Price  then in  effect  shall  be  reduced  to a price  equal to the
consideration  per share paid for such  securities.  Accordingly,  the  Exercise
Price  of the  Warrant  will be  adjusted  to  reflect  the same  percentage  of
reduction as in the Conversion Price adjustment, subject to customary carve outs
and to any  instruments  convertible or exercisable  for Common Stock and/or the
issuance of Common Stock thereto that were executed prior to the date hereof.

         (c) Stock Dividends,  Subdivisions and Combinations. If at any time the
Issuer shall:

                           (i)  make  or  issue  or set a  record  date  for the
         holders  of its  Common  Stock for the  purpose  of  entitling  them to
         receive a dividend  payable  in, or other  distribution  of,  shares of
         Common Stock,

                           (ii) effect a stock split of its  outstanding  shares
         of Common Stock into a larger number of shares of Common Stock, or

                           (iii) combine its outstanding  shares of Common Stock
         into a smaller number of shares of Common Stock,

                                       5
<PAGE>

then (1) the  number  of  shares of Common  Stock  for  which  this  Warrant  is
exercisable immediately after the occurrence of any such event shall be adjusted
to equal the number of shares of Common Stock which a record  holder of the same
number of  shares  of  Common  Stock  for  which  this  Warrant  is  exercisable
immediately  prior to the  occurrence  of such event would own or be entitled to
receive  after the  happening of such event,  and (2) the Warrant  Price then in
effect  shall  be  adjusted  to  equal  (A) the  Warrant  Price  then in  effect
multiplied  by the number of shares of Common  Stock for which  this  Warrant is
exercisable  immediately  prior to the  adjustment  divided by (B) the number of
shares of Common Stock for which this Warrant is exercisable  immediately  after
such adjustment.

Notwithstanding  the  foregoing,  if such  record date shall have been fixed and
such dividend is not fully paid or if such distribution is not fully made on the
date fixed  therefor,  the  Warrant  Price  shall be  adjusted  pursuant to this
paragraph as of the time of actual payment of such dividends or distributions.

         (d) Certain Other  Distributions.  If at any time the Issuer shall make
or issue or set a record date for the determination of the holders of its Common
Stock for the  purpose  of  entitling  them to  receive  any  dividend  or other
distribution of:

            (i)   cash  (other than a cash  dividend  payable out of earnings or
                  earned surplus legally  available for the payment of dividends
                  under the laws of the  jurisdiction  of  incorporation  of the
                  Issuer),

            (ii)  any evidences of its indebtedness,  any shares of stock of any
                  class  or any  other  securities  or  property  of any  nature
                  whatsoever  (other  than cash,  Common  Stock  Equivalents  or
                  Additional Shares of Common Stock), or

            (iii) any warrants or other rights to subscribe  for or purchase any
                  evidences  of its  indebtedness,  any  shares  of stock of any
                  class  or any  other  securities  or  property  of any  nature
                  whatsoever  (other  than cash,  Common  Stock  Equivalents  or
                  Additional Shares of Common Stock),

then (1) the  number  of  shares of Common  Stock  for  which  this  Warrant  is
exercisable  shall be  adjusted  to equal the product of the number of shares of
Common Stock for which this  Warrant is  exercisable  immediately  prior to such
adjustment  multiplied by a fraction (A) the numerator of which shall be the Per
Share Market Value of Common Stock at the date of taking such record and (B) the
denominator  of which  shall be such Per Share  Market  Value  minus the  amount
allocable to one share of Common Stock of any such cash so distributable  and of
the fair value (as  determined  in good faith by the Board of  Directors  of the
Issuer and supported by an opinion from an investment banking firm of recognized
national standing acceptable to (but not affiliated with) the Holder) of any and
all such  evidences  of  indebtedness,  shares of  stock,  other  securities  or
property or warrants or other  subscription or purchase rights so distributable,
and (2) the  Warrant  Price then in effect  shall be  adjusted  to equal (A) the
Warrant Price then in effect  multiplied by the number of shares of Common Stock
for which  this  Warrant  is  exercisable  immediately  prior to the  adjustment
divided  by (B) the number of shares of Common  Stock for which this  Warrant is
exercisable immediately after such adjustment.  A reclassification of the Common
Stock  (other  than a change in par value,  or from par value to no par value or
from no par value to par value)  into  shares of Common  Stock and shares of any
other class of stock shall be deemed a distribution by the Issuer to the holders
of its  Common  Stock of such  shares of such  other  class of stock  within the
meaning of this  Section  4(c) and, if the  outstanding  shares of Common  Stock
shall be changed into a larger or smaller  number of shares of Common Stock as a
part of such  reclassification,  such change  shall be deemed a  subdivision  or
combination,  as the case may be, of the  outstanding  shares  of  Common  Stock
within the meaning of Section 4(b).

                                       6
<PAGE>

Notwithstanding  the  foregoing,  if such  record date shall have been fixed and
such dividend is not fully paid or if such distribution is not fully made on the
date fixed  therefor,  the  Warrant  Price  shall be  adjusted  pursuant to this
Section  4(d)  as  of  the  time  of  actual   payment  of  such   dividends  or
distributions.

         (e) Purchase of Common  Stock by the Issuer.  If the Issuer at any time
while this  Warrant is  outstanding  shall,  directly  or  indirectly  through a
Subsidiary or  otherwise,  purchase,  redeem or otherwise  acquire any shares of
Common Stock at a price per share greater than the Per Share Market Value,  then
the Warrant Price upon each such purchase,  redemption or  acquisition  shall be
adjusted  to that  price  determined  by  multiplying  such  Warrant  Price by a
fraction (i) the numerator of which shall be the number of shares of Outstanding
Common Stock immediately prior to such purchase, redemption or acquisition minus
the number of shares of Common Stock which the aggregate  consideration  for the
total number of such shares of Common Stock so  purchased,  redeemed or acquired
would purchase at the Per Share Market Value;  and (ii) the denominator of which
shall be the number of shares of Outstanding Common Stock immediately after such
purchase,  redemption or acquisition.  For the purposes of this subsection,  the
date as of which the Per  Share  Market  Price  shall be  computed  shall be the
earlier of (x) the date on which the Issuer shall enter into a firm contract for
the purchase, redemption or acquisition of such Common Stock, or (y) the date of
actual  purchase,  redemption  or  acquisition  of such  Common  Stock.  For the
purposes of this subsection,  a purchase,  redemption or acquisition of a Common
Stock  Equivalent  shall be deemed to be a  purchase  of the  underlying  Common
Stock,  and the  computation  herein  required shall be made on the basis of the
full  exercise,  conversion  or exchange of such Common Stock  Equivalent on the
date as of which such computation is required hereby to be made,  whether or not
such  Common  Stock   Equivalent  is  actually   exercisable,   convertible   or
exchangeable on such date.

         (f) Other Provisions  applicable to Adjustments under this Section. The
following  provisions  shall be applicable to the making of  adjustments  of the
number of shares of Common Stock for which this Warrant is  exercisable  and the
Warrant Price then in effect provided for in this Section 4:

                  (i) Fractional Interests.  In computing adjustments under this
Section 4,  fractional  interests in Common Stock shall be taken into account to
the nearest one one-hundredth (1/100th) of a share.

                  (ii) When Adjustment Not Required.  If the Issuer shall take a
record of the holders of its Common Stock for the purpose of  entitling  them to
receive a dividend or distribution or subscription or purchase rights and shall,
thereafter and before the distribution to stockholders thereof,  legally abandon
its plan to pay or deliver such dividend, distribution, subscription or purchase
rights,  then thereafter no adjustment shall be required by reason of the taking
of such record and any such adjustment  previously made in respect thereof shall
be rescinded and annulled.

         (g) Form of Warrant  after  Adjustments.  The form of this Warrant need
not be changed because of any adjustments in the Warrant Price or the number and
kind of Securities purchasable upon the exercise of this Warrant.

         (h)  Escrow  of  Warrant   Stock.   If  after  any   property   becomes
distributable  pursuant to this  Section 4 by reason of the taking of any record
of the holders of Common  Stock,  but prior to the  occurrence  of the event for
which such record is taken, and the Holder exercises this Warrant, any shares of
Common Stock issuable upon exercise by reason of such adjustment shall be deemed
the  last  shares  of  Common   Stock  for  which  this   Warrant  is  exercised
(notwithstanding  any other provision to the contrary herein) and such shares or
other property shall be held in escrow for the Holder by the Issuer to be issued
to the Holder upon and to the extent that the event actually  takes place,  upon
payment of the current Warrant Price. Notwithstanding any other provision to the
contrary herein,  if the event for which such record was taken fails to occur or
is  rescinded,  then such  escrowed  shares shall be cancelled by the Issuer and
escrowed property returned.

                                       7
<PAGE>

         5. Notice of  Adjustments.  Whenever the Warrant Price or Warrant Share
Number  shall be adjusted  pursuant  to Section 4 hereof  (for  purposes of this
Section 5, each an  "adjustment"),  the Issuer  shall cause its Chief  Financial
Officer to prepare  and  execute a  certificate  setting  forth,  in  reasonable
detail,  the event requiring the adjustment,  the amount of the adjustment,  the
method by which such  adjustment was calculated  (including a description of the
basis on which the Board  made any  determination  hereunder),  and the  Warrant
Price and Warrant Share Number after giving effect to such adjustment, and shall
cause copies of such  certificate  to be delivered to the Holder of this Warrant
promptly after each adjustment. Any dispute between the Issuer and the Holder of
this Warrant with  respect to the matters set forth in such  certificate  may at
the option of the Holder of this  Warrant be  submitted  to one of the  national
accounting  firms  currently  known as the "big four"  selected  by the  Holder,
provided  that the Issuer shall have ten (10) days after  receipt of notice from
such Holder of its selection of such firm to object thereto,  in which case such
Holder shall select another such firm and the Issuer shall have no such right of
objection.  The firm  selected by the Holder of this  Warrant as provided in the
preceding  sentence shall be instructed to deliver a written  opinion as to such
matters to the Issuer and such Holder within  thirty (30) days after  submission
to it of such  dispute.  Such opinion  shall be final and binding on the parties
hereto.

         6.  Fractional  Shares.  No fractional  shares of Warrant Stock will be
issued in connection  with any exercise  hereof,  but in lieu of such fractional
shares;  the Issuer  shall make a cash payment  therefor  equal in amount to the
product of the applicable fraction multiplied by the Per Share Market Value then
in effect.

         7.  Registration  Rights.  The  shares of Common  Stock  issuable  upon
exercise  of this  Warrant  shall  have  piggyback  registration  rights  and be
included in the next  registration  statement the Company files with the SEC and
such registration  statement will be kept effective for a period of three years,
subject to customary carve-outs.

         8. Definitions.  For the purposes of this Warrant,  the following terms
have the following meanings:

                  "Articles   of   Incorporation"    means   the   Articles   of
         Incorporation  of the Issuer as in effect on the  Original  Issue Date,
         and as hereafter from time to time amended,  modified,  supplemented or
         restated in  accordance  with the terms hereof and thereof and pursuant
         to applicable law.

                  "Board" shall mean the Board of Directors of the Issuer.

                  "Capital  Stock"  means and  includes  (i) any and all shares,
         interests,  participations  or other  equivalents  of or  interests  in
         (however designated)  corporate stock,  including,  without limitation,
         shares of preferred or preference stock, (ii) all partnership interests
         (whether  general or  limited)  in any Person  which is a  partnership,
         (iii) all membership  interests or limited  liability company interests
         in any  limited  liability  company,  and (iv) all equity or  ownership
         interests in any Person of any other type.

                  "Common  Stock" means the Common  Stock,  par value $.0005 per
         share,  of the Issuer and any other Capital Stock into which such stock
         may hereafter be changed.

                  "Convertible  Securities"  means  evidences  of  Indebtedness,
         shares of Capital Stock or other  Securities which are or may be at any
         time convertible  into or exchangeable for Additional  Shares of Common
         Stock.  The term  "Convertible  Security"  means one of the Convertible
         Securities.

                                       8
<PAGE>

                  "Governmental Authority" means any governmental, regulatory or
         self-regulatory   entity,   department,   body,  official,   authority,
         commission, board, agency or instrumentality, whether federal, state or
         local, and whether domestic or foreign.

                  "Holders" mean the Persons who shall from time to time own any
         Warrant. The term "Holder" means one of the Holders.

                  "Independent Appraiser" means a nationally recognized or major
         regional  investment  banking  firm or firm  of  independent  certified
         public  accountants of recognized  standing (which may be the firm that
         regularly  examines  the  financial  statements  of the Issuer) that is
         regularly  engaged in the business of  appraising  the Capital Stock or
         assets of corporations  or other entities as going concerns,  and which
         is not affiliated with either the Issuer or the Holder of any Warrant.

                  "Issuer"  means  Medical  Media  Television,  Inc.,  a Florida
         corporation, and its successors.

                  "Majority  Holders"  means at any time the Holders of Warrants
         exercisable  for a majority  of the shares of  Warrant  Stock  issuable
         under the Warrants at the time outstanding.

                  "Original Issue Date" means March 31, 2006.

                  "OTC  Bulletin  Board" means the  over-the-counter  electronic
         bulletin board.

                  "Other  Common" means any other Capital Stock of the Issuer of
         any class which shall be  authorized at any time after the date of this
         Warrant  (other  than  Common  Stock) and which shall have the right to
         participate  in the  distribution  of earnings and assets of the Issuer
         without limitation as to amount.

                  "Outstanding  Common  Stock"  means,  at any given  time,  the
         aggregate amount of outstanding  shares of Common Stock,  assuming full
         exercise,  conversion  or  exchange  (as  applicable)  of all  options,
         warrants and other Securities which are convertible into or exercisable
         or  exchangeable  for, and any right to subscribe for, shares of Common
         Stock that are outstanding at such time.

                  "Person" means an individual,  corporation,  limited liability
         company,  partnership,   joint  stock  company,  trust,  unincorporated
         organization,  joint venture, Governmental Authority or other entity of
         whatever nature.

                  "Per Share Market Value" means on any particular  date (a) the
         closing bid price for a share of Common  Stock in the  over-the-counter
         market,  as  reported  by the OTC  Bulletin  Board  or in the  National
         Quotation  Bureau  Incorporated  or  similar   organization  or  agency
         succeeding  to its  functions  of  reporting  prices)  at the  close of
         business on such date,  or (b) if the Common Stock is not then reported
         by the OTC Bulletin Board or the National Quotation Bureau Incorporated
         (or similar  organization  or agency  succeeding  to its  functions  of
         reporting prices),  then the average of the "Pink Sheet" quotes for the
         relevant  conversion period, as determined in good faith by the holder,
         or (c) if the Common Stock is not then publicly  traded the fair market
         value of a share of  Common  Stock as  determined  by the Board in good
         faith;  provided,  however, that the Majority Holders, after receipt of
         the determination by the Board, shall have the right to select, jointly
         with the Issuer,  an  Independent  Appraiser,  in which case,  the fair
         market value shall be the determination by such Independent  Appraiser;
         and provided,  further that all  determinations of the Per Share Market
         Value shall be appropriately  adjusted for any stock  dividends,  stock
         splits  or  other  similar   transactions   during  such  period.   The
         determination  of fair market value shall be based upon the fair market
         value of the Issuer  determined  on a going  concern basis as between a
         willing buyer and a willing seller and taking into account all relevant
         factors  determinative  of value, and shall be final and binding on all
         parties.  In determining  the fair market value of any shares of Common
         Stock, no consideration  shall be given to any restrictions on transfer
         of the  Common  Stock  imposed  by  agreement  or by  federal  or state
         securities  laws, or to the existence or absence of, or any limitations
         on, voting rights.

                                       9
<PAGE>

                  "Securities"  means  any  debt  or  equity  securities  of the
         Issuer, whether now or hereafter authorized, any instrument convertible
         into or  exchangeable  for  Securities  or a Security,  and any option,
         warrant or other right to purchase or acquire any Security.  "Security"
         means one of the Securities.

                  "Securities Act" means the Securities Act of 1933, as amended,
         or any similar federal statute then in effect.

                  "Subsidiary"  means  any  corporation  at  least  50% of whose
         outstanding  Voting  Stock  shall  at the  time be  owned  directly  or
         indirectly by the Issuer or by one or more of its  Subsidiaries,  or by
         the Issuer and one or more of its Subsidiaries.

                  "Term" has the meaning specified in Section 1 hereof.

                  "Trading  Day"  means (a) a day on which the  Common  Stock is
         traded on the OTC  Bulletin  Board,  or (b) if the Common  Stock is not
         traded on the OTC  Bulletin  Board,  a day on which the Common Stock is
         quoted in the  over-the-counter  market  as  reported  by the  National
         Quotation Bureau  Incorporated  (or any similar  organization or agency
         succeeding its functions of reporting prices); provided,  however, that
         in the event that the Common Stock is not listed or quoted as set forth
         in (a) or (b)  hereof,  then  Trading  Day  shall  mean any day  except
         Saturday, Sunday and any day which shall be a legal holiday or a day on
         which banking  institutions  in the State of New York are authorized or
         required by law or other government action to close.

                  "Voting  Stock" means,  as applied to the Capital Stock of any
         corporation, Capital Stock of any class or classes (however designated)
         having  ordinary  voting  power for the  election  of a majority of the
         members of the Board of  Directors  (or other  governing  body) of such
         corporation,  other than Capital Stock having such power only by reason
         of the happening of a contingency.

                  "Warrants" means this Warrant,  and any other warrants of like
         tenor issued in  substitution  or exchange for any thereof  pursuant to
         the  provisions of Section 2(c),  2(d) or 2(e) hereof or of any of such
         other Warrants.

                  "Warrant  Price"  initially  means U.S.  $.75 as such  Warrant
         Price  may be  adjusted  from  time to time as  shall  result  from the
         adjustments specified in this Warrant, including Section 4 hereto.

                  "Warrant Share Number" means at any time the aggregate  number
         of shares of Warrant  Stock  which may at such time be  purchased  upon
         exercise of this Warrant,  after giving effect to all prior adjustments
         and  increases  to such  number  made or  required to be made under the
         terms hereof.

                                       10
<PAGE>

                  "Warrant  Stock" means Common Stock  issuable upon exercise of
         any Warrant or Warrants or otherwise  issuable  pursuant to any Warrant
         or Warrants.

         9. Other Notices. In case at any time:

                        (A)   the  Issuer  shall make any  distributions  to the
                              holders of Common Stock; or

                        (B)   the Issuer  shall  authorize  the  granting to all
                              holders of its Common Stock of rights to subscribe
                              for or purchase any shares of Capital Stock of any
                              class or other rights; or

                        (C)   there shall be any reclassification of the Capital
                              Stock of the Issuer; or

                        (D)   there shall be any capital  reorganization  by the
                              Issuer; or

                        (E)   there  shall be any (i)  consolidation  or  merger
                              involving  the  Issuer or (ii) sale,  transfer  or
                              other  disposition of all or substantially  all of
                              the Issuer's property,  assets or business (except
                              a merger  or  other  reorganization  in which  the
                              Issuer shall be the surviving  corporation and its
                              shares  of  Capital  Stock  shall  continue  to be
                              outstanding    and    unchanged   and   except   a
                              consolidation,  merger,  sale,  transfer  or other
                              disposition involving a wholly-owned  Subsidiary);
                              or

                        (F)   there   shall  be  a  voluntary   or   involuntary
                              dissolution,  liquidation  or  winding-up  of  the
                              Issuer or any partial liquidation of the Issuer or
                              distribution to holders of Common Stock;

then, in each of such cases,  the Issuer shall give written notice to the Holder
of the date on which (i) the books of the Issuer  shall close or a record  shall
be taken for such dividend,  distribution  or  subscription  rights or (ii) such
reorganization,    reclassification,    consolidation,    merger,   disposition,
dissolution,  liquidation or  winding-up,  as the case may be, shall take place.
Such notice also shall  specify the date as of which the holders of Common Stock
of record shall  participate  in such  dividend,  distribution  or  subscription
rights, or shall be entitled to exchange their certificates for Common Stock for
securities   or   other   property   deliverable   upon   such   reorganization,
reclassification,  consolidation, merger, disposition,  dissolution, liquidation
or  winding-up,  as the case may be. Such notice  shall be given at least twenty
(20) days prior to the record date or effective date for the event  specified in
such notice.

         10. Amendment and Waiver. Any term, covenant, agreement or condition in
this  Warrant may be amended,  or  compliance  therewith  may be waived  (either
generally   or  in  a   particular   instance   and  either   retroactively   or
prospectively),  by a written instrument or written instruments  executed by the
Issuer and the Majority Holders;  provided,  however,  that no such amendment or
waiver  shall  reduce the Warrant  Share  Number,  increase  the Warrant  Price,
shorten the period  during  which this  Warrant may be  exercised  or modify any
provision of this Section 11 without the consent of the Holder of this Warrant.

         11.  Governing  Law. THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE  WITH THE LAWS OF THE  STATE OF  FLORIDA,  WITHOUT  GIVING  EFFECT TO
PRINCIPLES OF CONFLICTS OF LAW.

                                       11
<PAGE>

         12. Notices.  Any and all notices or other communications or deliveries
required or permitted to be provided  hereunder shall be in writing and shall be
deemed given and  effective on the earlier of (i) the date of  transmission,  if
such  notice or  communication  is  delivered  via  facsimile  at the  facsimile
telephone  number  specified  for notice prior to 5:00 p.m.,  eastern time, on a
Trading Day, (ii) the Trading Day after the date of transmission, if such notice
or  communication  is delivered via facsimile at the facsimile  telephone number
specified for notice later than 5:00 p.m., eastern time, on any date and earlier
than 11:59 p.m., eastern time, on such date, (iii) the Trading Day following the
date  of  mailing,  if sent  by  overnight  delivery  by  nationally  recognized
overnight  courier  service  or (iv)  actual  receipt  by the party to whom such
notice is required to be given. The addresses for such  communications  shall be
with respect to the Holder of this Warrant or of Warrant  Stock issued  pursuant
hereto,  addressed to such Holder at its last known address or facsimile  number
appearing  on the books of the  Issuer  maintained  for such  purposes,  or with
respect to the Issuer, addressed to:

                        Medical Media Television, Inc.
                        8406 Benjamin Road, Suite C
                        Tampa, Florida 33634
                        Attention: Philip M. Cohen, President and CEO
                        Tel. No.: (813) 888-7330
                        Fax No.:  (813) 888-7375

Copies of  notices  to the Issuer  shall be sent to Bush Ross  Gardner  Warren &
Rudy, P.A., Attn: John N. Giordano, 220 S. Franklin Street, Tampa, FL 33601, Tel
No. (813)  224-9255,  Fax. No. (813)  224-9230.  Copies of notices to the Holder
shall be sent to Elaine G. Edinburg,  PO Box 2742,  Edwards, CO 81632, Tel. No.:
(970) 926-1177,  Fax No.: (970) 926-4067. Any party hereto may from time to time
change its address for notices by giving at least ten (10) days  written  notice
of such changed address to the other party hereto.

         13. Warrant Agent.  The Issuer may, by written notice to each Holder of
this  Warrant,  appoint  an agent  having an office  in Tampa,  Florida  for the
purpose  of issuing  shares of Warrant  Stock on the  exercise  of this  Warrant
pursuant to subsection (b) of Section 2 hereof, exchanging this Warrant pursuant
to  subsection  (d) of Section 2 hereof or replacing  this  Warrant  pursuant to
subsection (d) of Section 3 hereof, or any of the foregoing,  and thereafter any
such  issuance,  exchange or  replacement,  as the case may be, shall be made at
such office by such agent.

         14.  Remedies.  The Issuer  stipulates  that the remedies at law of the
Holder of this Warrant in the event of any default or threatened  default by the
Issuer in the performance of or compliance with any of the terms of this Warrant
are not and will not be adequate and that,  to the fullest  extent  permitted by
law,  such  terms may be  specifically  enforced  by a decree  for the  specific
performance  of any agreement  contained  herein or by an  injunction  against a
violation of any of the terms hereof or otherwise.

         15.  Successors  and  Assigns.  This  Warrant and the rights  evidenced
hereby  shall inure to the  benefit of and be binding  upon the  successors  and
assigns of the Issuer, the Holder hereof and (to the extent provided herein) the
Holders of Warrant Stock issued pursuant hereto, and shall be enforceable by any
such Holder or Holder of Warrant Stock.

         16.  Modification and Severability.  If, in any action before any court
or agency  legally  empowered to enforce any  provision  contained  herein,  any
provision  hereof is found to be  unenforceable,  then such  provision  shall be
deemed modified to the extent  necessary to make it enforceable by such court or
agency.  If any such provision is not  enforceable as set forth in the preceding
sentence,  the  unenforceability  of such  provision  shall not affect the other
provisions  of this  Warrant,  but this  Warrant  shall be  construed as if such
unenforceable provision had never been contained herein.

                                       12
<PAGE>

         17.  Headings.  The  headings of the  Sections of this  Warrant are for
convenience of reference  only and shall not, for any purpose,  be deemed a part
of this Warrant.

         IN WITNESS WHEREOF,  the Issuer has executed this Warrant as of the day
and year first above written.

                                   MEDICAL MEDIA TELEVISION, INC.

                                   By: /s/ Philip M. Cohen
                                       -----------------------------------------
                                       Philip M. Cohen
                                       President and Chief Executive Officer

                                       13
<PAGE>

                                  EXERCISE FORM

                         MEDICAL MEDIA TELEVISION, INC.

The  undersigned  _______________,  pursuant  to the  provisions  of the  within
Warrant, hereby elects to purchase _____ shares of Common Stock of Medical Media
Television, Inc. covered by the within Warrant.

Dated: _________________            Signature __________________________________

                                    Address   __________________________________

Number of shares of Common Stock beneficially owned or deemed beneficially owned
by the Holder on the date of Exercise: _________________________

                                   ASSIGNMENT

FOR VALUE RECEIVED,  _________________  hereby sells, assigns and transfers unto
__________________  the within Warrant and all rights evidenced thereby and does
irrevocably constitute and appoint _____________, attorney, to transfer the said
Warrant on the books of the within named corporation.

Dated: _________________            Signature __________________________________

                                    Address   __________________________________

                               PARTIAL ASSIGNMENT

FOR VALUE RECEIVED,  _________________  hereby sells, assigns and transfers unto
__________________  the right to  purchase  _________  shares of  Warrant  Stock
evidenced  by the within  Warrant  together  with all rights  therein,  and does
irrevocably  constitute and appoint  ___________________,  attorney, to transfer
that part of the said Warrant on the books of the within named corporation.

Dated: _________________            Signature __________________________________

                                    Address   __________________________________

                           FOR USE BY THE ISSUER ONLY:

This Warrant No. W-___ canceled (or  transferred or exchanged) this _____ day of
___________,  _____,  shares  of Common  Stock  issued  therefor  in the name of
_______________,  Warrant No.  W-_____ issued for ____ shares of Common Stock in
the name of _______________.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}]]